SavedAdd your journal

Journals / Genel Tıp Dergisi / 1997 / Cilt: 7 - Sayı: 3

A comparison of local and systemic complications of intravenous and submucosal injection of cyclophosphamide in rabbits

Tavşanlarda anal submukozal veya intravenöz yolla uygulanan siklofosfamidin lokal ve sistemik komplikasyonlarının karşılaştırılması

Mehmet ÇERÇİ
Salim GÜNGÖR
Kadir YILMAZ
Ethem ÖMEROĞLU
A. İhsan GÜLEÇ
Ayşe YAVUZ
Mehmet YÜNCÜ
Pages
125–127
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Anal submucosal injection of cyclophosphamide are preferable.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In this study it was aimed to compare side effects of cyclophosphamide applied by anal submucosal and intravenous route.
📊
Key Findings & Data:Methods: Cyclophosphamide was given to 10 rabbits intravenously, to 10 rabbits by anal submucosal injection for 20 days.
💡
Conclusion & Impact:Conclusion: Anal submucosal injection of cyclophosphamide are preferable.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: In this study it was aimed to compare side effects of cyclophosphamide applied by anal submucosal and intravenous route. Methods: Cyclophosphamide was given to 10 rabbits intravenously, to 10 rabbits by anal submucosal injection for 20 days. After the termination of the experiment, the specimens were prepared from liver, kidneys and rectum. Results: Microscopical investigation revealed that intravenous injections contributed to degenerated areas in the liver of rabbits while anal submucosal injection group did not show any recognizable damage in the tissues examined. Conclusion: Anal submucosal injection of cyclophosphamide are preferable.

Özet

Amaç: Bu çalışmada anal submukozal ve intravenöz yolla uygulanan siklofosfamidin lokal ve sistemik yan etkilerini karşılaştırmak amaçlanmıştır. Yöntem: 20 gün süre ile 10 tavşana intravenöz, 10 tavşana anal mukozal yolla siklofosfamid verildi. Deneyin sonuçlanmasından sonra karaciğer, böbrekler ve rektumdan numuneler hazırlandı. Bulgular: Mikroskopik incelemede intravenöz injeksiyon yapılan grupta karaciğer dejenerasyon sahaları görülürken, anal submukozal injeksiyon grubunda dokularda dikkate değer bulguya rastlanmadı. Sonuç: Siklofosfamidin anal submukozal uygulanması tercih edilebilir.

🔖

Cite This Article

ÇERÇİ, M., GÜNGÖR, S., YILMAZ, K., ÖMEROĞLU, E., GÜLEÇ, A. İ., YAVUZ, A., YÜNCÜ, M. (1997). A comparison of local and systemic complications of intravenous and submucosal injection of cyclophosphamide in rabbits. Genel Tıp Dergisi, Cilt: 7 - Sayı: 3, 125–127. https://ajindex.com/articles/225188

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Yagoda A, Watson RC, Grastald H. Adriamycine and cylophosphamide in advanced bladder cancer. Cancer Treat Rep 1977;61:97. Soloway MS. Selecting initial therapy for bladder cancer. Cancer 1987;53 Suppl:510-2.
  2. Shafik A, Haddat S. Anal submucosal injection: A new route for drug administration in pelvic malignancies-1: Methotrexate anal injection in the treatment of advanced bladder cancer. J Urol 1988;140:501-5.
  3. Shafik A, El-Merzabani MM, El-Aaeser AA, El-Desouky GMT. Anal submucosal injection: A new route for drug administration in serum and tissues with special reference to urinary bladder: Preliminary report. Invest Rad 1986;21:278. Kayaalp O. Tıbbi Farmakoloji. Ankara: Toraman ve Ulucan Matbaası; 1987.
  4. Calabresi P, Parks ER. Chemotherapy of neoplastic disease. In: The pharmacological basis of therapeutics. Goodman SL, Gilman A, editors. New York: Mc Millan Publishing Co; 1975.
  5. Goldberg JW, Lidsky MD. Cylophosphamide associated hepatotoxicity. Southern Med J 1985;78:222-3.
  6. Yılmaz K, Kılınç M, Bozoklu H, Sezer AN. Tavşanlarda Tc-99m ile işaretlenmiş siklofosfamidin intravenöz anal submukozal injeksiyonunun karşılaştırılması. SÜ Tıp Fak Derg 1991;7:173-5.
  7. Gurtool HL, Bansal SK, Pavelic Z, Struck RF. Effects of the induction of hepatic microsomal metabolism on the toxicity of cylophosphamide. Br J Cancer 1985;51:67-75. Cox PJ. Cylophosphamide cystitis-idendification of acrolein as causative agent. Biochem Pharmacol 1979;28:2045.
  8. Berrigan MJ, Marinello AJ, Pavelic Z, Williams CJ, Struck RF, Gurtoo HL. Protective role of thiols in cylophosphamide induced urotoxicity and depression of hepatic drug metabolism. Cancer Res 1982;42:3688.